The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...

The latest strain of the COVID-19 virus, XEC, is circulating across the country. The new variant has been reported in at ...

As you can see below, at the end of June 2024, Pfizer had US$69.9b of debt, up from US$65.7b a year ago. Click the image for ...

We recently compiled a list of the Best Future Stocks For The Long-Term. In this article, we will look at where Pfizer Inc.

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Shares of Pfizer Inc. PFE dropped 0.81% to $29.42 Friday, on what proved to be an all-around mixed trading session for the ...

New, more expensive migraine drugs are no more effective against the throbbing headaches than traditional painkillers, and ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use ...

With COVID cases on the rise in many countries, the race to find an effective vaccine is becoming a more pressing concern ...